Roshan Bodhe^a*, Surajkumar Ram^b, Rajendra Shinde^c, Kishor Patil^c

^aDepartment of Pharmaceutics R.C.Patel Institute of Pharmaceutical Education and Research, Near Karwand, Naka Shirpur, Dist–Dhule 425405, Maharashtra, India

^bDepartment of Biotechnology National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Sector-67, Mohali, Punjab-160062, India

^cDepartment of Pharmaceutical Science, London Metropolitan University, Hollyway Road London -166-220, United Kingdom

*Corresponding author: Roshan Gomaji Bodhe, Department of Pharmaceutics R.C.Patel Institute of Pharmaceutical Education and Research, Near Karwand, Naka ShirpurDist –Dhule 425405, Maharashtra, India. 

Citation: Roshan B, Surajkumar R, Rajendra S, Kishor P (2022) Formulation Development and Evaluation of Injectable Depot Suspension. Int J Med Healthcare Rep, 1(2); 1-12

Copyright: © 2022, Roshan Gomaji Bodhe. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract:

The aim of the present study was to develop sustained release parenteral depot drug delivery system of contraceptive drug (Medroxyprogesteron acetate). Parenteral depots formulations (suspension) are widely used to improve therapeutic value of water insoluble drug’s & provide sustained drug release over a longer duration of time and solve the problem of daily intake of medicine. Long acting hormonal contraceptive depot formulation advanced the practice of contraception, where injectable & subdermal route of administration used. Objective of present study was to develop medroxyprogesteron acetate injectable depot suspension for contraceptive used. Medroxyprogesteron acetate injectable depot suspensions were prepared by sterile combining of API and excipient powders by rapid stirring method. Mixing speed and temperature dependent solubility of parabens were affect the particle size, specific surface area and dissolution rate of given suspension. Different excipients used in the formulation are Methylparaben & Propyllparaben used as preservative and re-suspending agent, sodium chloride were used Isotonisity modifier, PEG 3350 were used as suspending agent, Tween 80 used as surfactant. The resultant MPA suspension were evaluated for Physical properties, MPA content were 101.00 ± 2 %, viscosity were 8.58 ±1cps, pH 5.826 ±1 and osmolality were found to be 378 ± 5 Mosmol /kg.H₂O respectively & further characterized for surface morphology, particle size, zeta potential sedimentation volume, syrengeability, hold time study, In vitro drug release. The suspensions were found to be spherical with smooth surface. Particle size, specific surface area & zeta potential were found to be (Particle size 13.4 µm with specific surface area 1530 cm²/km, -22.66 mV). Interaction between the drug and polymer were investigated by Fourier Transform Infrared (FT-IR) Spectroscopy. The MPA injectable suspension could go through 24 gauge hypodermic needle smoothly with withdrawal volume 1.70, mL, MPA suspension re-dispersed within 1 minute without forming clogs. The FT-IR analysis confirmed the compatibility of MPA with the excipients without interaction. In- vitro drug release from these MPA injectable suspension showed sustained release over a period of 48 hours (Dissolution type-II apparatus), & 90 minute (Dissolution type- IV apparatus).